Evolution of testosterone treatment over 25 years: symptom responses, endocrine profiles and cardiovascular changes

References

• Hall SA, Ranganathan G, Tinsley LJ, et al. Population-based patterns of prescription androgen use, 1976–2008. Pharmacoepidemiol Drug Saf 2014;23:498–506
   PubMed Web of Science ®Google Scholar
• Nieschlag S, Behre HM. Testosterone: action, deficiency, substitution. 4th edn. Cambridge, UK: Cambridge University Press; 2012
   Google Scholar
• Heinemann LAJ, Zimmermann T, Vermeulen A, et al. A new aging males’ symptoms (AMS) rating scale. Aging Male 1999;2:105–14
   Google Scholar
• Carruthers M. Androgen deficiency in the adult male – causes, diagnosis and treatment. Boca Raton, FL: CRC Press; 2004
   Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666–72
   PubMed Web of Science ®Google Scholar
• Carruthers M, Trinick TR, Wheeler MJ. The validity of androgen assays. Aging Male 2007;10:165–72
   PubMed Web of Science ®Google Scholar
• Morales A, Spevack M, Emerson L, et al. Adding to the controversy: pitfalls in the diagnosis of testosterone deficiency syndromes with questionnaires and biochemistry. Aging Male 2007;10:57–65
   PubMed Web of Science ®Google Scholar
• Miwa Y, Kaneda T, Yokoyama O. Correlation between the Aging Males’ Symptoms Scale and sex steroids, gonadotropins, dehydroepiandrosterone sulfate, and growth hormone levels in ambulatory men. J Sex Med 2006;3:723–6
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Khera M, Maggi M, Zitzmann M. Commentary: who is a candidate for testosterone therapy? A synthesis of international expert opinions. J Sex Med 2014;11:1636–45
   PubMed Web of Science ®Google Scholar
• McCullough AR, Khera M, Goldstein I, et al. A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel(R)) insertion. J Sex Med 2012;9:594–601
   PubMed Web of Science ®Google Scholar
• Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89:2085–98
   PubMed Web of Science ®Google Scholar
• Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000;85:4500–10
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Mattern A, Hanisch J, et al. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1438 men. J Sex Med 2013;10:579–88
   PubMed Web of Science ®Google Scholar
• Atkinson LE, Chang Y, Snyder PJ. Long-term experience with testosterone replacement through scrotal skin. In Testosterone: Action, deficiency, substitution. 2 edn. Berlin. Springer Verlag; 365--88
   Google Scholar
• Behre HM, von Eckardstein S, Kliesch S, Nieschlag E. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7–10 years. Clin Endocrinol (Oxf) 1999;50:629–35
   PubMed Web of Science ®Google Scholar
• Feneley MR, Carruthers M. Is testosterone treatment good for the prostate? Study of safety during long-term treatment. J Sex Med 2012;9:2138–49
   PubMed Web of Science ®Google Scholar
• Moskovic DJ, Araujo AB, Lipshultz LI, Khera M. The 20-year public health impact and direct cost of testosterone deficiency in U.S. men. J Sex Med 2013;10:562–9
   PubMed Web of Science ®Google Scholar
• Arver S, Luong B, Fraschke A, et al. Is testosterone replacement therapy in males with hypogonadism cost-effective? An analysis in Sweden. J Sex Med 2013;11:262–72
   PubMed Web of Science ®Google Scholar
• Hackett G, Cole N, Bhartia M, et al. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med 2014;11:840–56
   PubMed Web of Science ®Google Scholar
• Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004;89:3813–17
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006;91:4335–43
   PubMed Web of Science ®Google Scholar
• Maganty A, Shoag JE, Ramasamy R. Testosterone threshold – does one size fit all?. Aging Male 2015;18:1–4
   PubMed Web of Science ®Google Scholar
• Carruthers M. The paradox dividing testosterone deficiency symptoms and androgen assays: a closer look at the cellular and molecular mechanisms of androgen action. J Sex Med 2008;5:998–1012
   PubMed Web of Science ®Google Scholar
• Anderson RA, Ludlam CA, Wu FC. Haemostatic effects of supraphysiological levels of testosterone in normal men. Thromb Haemost 1995;74:693–7
   PubMed Web of Science ®Google Scholar
• Om AS, Chung KW. Dietary zinc deficiency alters 5 alpha-reduction and aromatization of testosterone and androgen and estrogen receptors in rat liver. J Nutr 1996;126:842–8
   PubMed Web of Science ®Google Scholar
• Traish AM, Guay AT, Morgentaler A. Death by testosterone? We think not!. J Sex Med. 2014;11:624–29
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male 2015;18:1–11
   PubMed Web of Science ®Google Scholar
• Yeap BB, Alfonso H, Chubb SA, et al. Reference ranges and determinants of testosterone, dihydrotestosterone, and estradiol levels measured using liquid chromatography-tandem mass spectrometry in a population-based cohort of older men. J Clin Endocrinol Metab 2012;97:4030–9
   PubMed Web of Science ®Google Scholar
• Sikaris K, McLachlan RI, Kazlauskas R, et al. Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. J Clin Endocrinol Metab 2005;90:5928–36
   PubMed Web of Science ®Google Scholar
• Yeap BB, Alfonso H, Chubb SA, et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J Clin Endocrinol Metab 2014;99:E9–18
   PubMed Web of Science ®Google Scholar